PD-1 and PD-L1 Inhibitors Market By Type (PD-1 (Pembrolizumab, Nivolumab, Etc.), PD-L1 (Atezolizumab, Avelumab, Etc.)); By Application (Non-small Cell Lung Cancer (NSCLC), Urothelial Carcinoma (UC), Esophageal Cancer, Melanoma, Head and Neck Cancer, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029

Report ID :AMI-1051 | Category : Healthcare | Published Date : February, 2022 | Pages : 420 | Format :PDF